Healthcare Industry News: Fresenius Medical Care
News Release - July 13, 2016
CytoSorbents Teams with Medial and Meditrade to Bring CytoSorb(R) to Hungary, Czech Republic, Slovakia, and PolandMONMOUTH JUNCTION, N.J., July 13, 2016 -- (Healthcare Sales & Marketing Network) -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has signed a formal exclusive distribution agreement with Medial, Ltd., to distribute CytoSorb® in Hungary. In a separate agreement, Meditrade Ltd. will distribute CytoSorb® for all critical care and cardiac surgery applications in the Czech Republic and Slovakia, and for cardiac surgery applications in Poland. Fresenius Medical Care will continue to distribute CytoSorb® in Poland for all critical care applications under the terms of an existing agreement. Both Medial and Meditrade are currently selling CytoSorb® in their respective territories. CytoSorbents Logo.CytoSorbents Logo. CytoSorbents Logo.
Mária Szucsné Pompor, Managing Director of Medial Ltd. stated, "We are very proud to have already successfully introduced CytoSorb®, the innovative and promising treatment for patients with a systemic inflammatory response syndrome, severe sepsis or septic shock, in Hungary. In our significant clinical experience so far, the adjuvant use of CytoSorb® extracorporeal therapy has been used to help control the excessive inflammatory response, remove certain bacterial toxins, and protect otherwise healthy organs in life-threatening illnesses. These positive clinical experiences obtained in the Hungarian University Clinics and major hospitals support our belief that CytoSorb® adjuvant therapy can efficiently and safely attenuate severe cytokine storm in cardiac surgery and in the ICU, promoting improved clinical outcomes and helping patients to survive."
Pavel Bohdal, Chief Executive Officer of Meditrade Ltd. remarked, "We are excited to continue our cooperation with CytoSorbents because CytoSorb® represents one of the newest therapeutic innovations in critical care and cardiac surgery, two areas that we specialize in. We have watched the rapid growth of CytoSorb® in many different countries and are pleased to be able to bring this revolutionary product to help patients in the Czech Republic, Slovakia, and Poland. We have seen the therapy work in the hands of our own physicians, giving us great confidence about the impact it will have on healthcare in the future."
"Medial and Meditrade are long-standing pioneers of novel medical therapies in their respective countries with excellent reputations, and we are delighted to be working with them," commented Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. "This is yet another step in our long-standing commitment to make CytoSorb® available to clinicians to help treat their patients globally."
CytoSorb® is now distributed in 37 countries throughout the world. Poland has a population of 38.5 million people, and Hungary, the Czech Republic, and Slovakia have a combined population of approximately 26.0 million people.
About Medial Ltd
Medial Ltd has been a reliable supplier of medical equipment and disposables to Hungarian healthcare institutions since 1992 and is headquartered in Budapest. Its business activity is focused on intensive care, OR and disinfection products. Its business strategy is based on the distribution of innovative, high quality medical technology products in the Hungarian health care market. For more information, please visit: www.medial.hu
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsCytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb(R) in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR(TM) Antithrombotic Removal System During Urgent Cardiothoracic Surgery
Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR(TM) Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery